Genome-wide CRISPR/Cas9 Screens Reveal Shared and Bespoke Mechanisms of Resistance to SHP2 inhibition
W Wei - 2023 - search.proquest.com
Abstract SHP2 (PTPN11) acts upstream of SOS1/2 to enable RAS activation. Allosteric
SHP2 inhibitors (SHP2i) in the clinic prevent SHP2 activation, block proliferation of RTK-or …
SHP2 inhibitors (SHP2i) in the clinic prevent SHP2 activation, block proliferation of RTK-or …
Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition
SHP2 (PTPN11) acts upstream of SOS1/2 to enable RAS activation. Allosteric SHP2
inhibitors (SHP2i) in the clinic prevent SHP2 activation, block proliferation of RTK-or cycling …
inhibitors (SHP2i) in the clinic prevent SHP2 activation, block proliferation of RTK-or cycling …
[HTML][HTML] Sidestepping SHP2 inhibition
Allosteric SHP2 inhibitors are a novel class of compounds that target hyperactive
Ras/Mitogen Activated Protein Kinase (MAPK) signaling. In this issue of JEM, Wei et …
Ras/Mitogen Activated Protein Kinase (MAPK) signaling. In this issue of JEM, Wei et …
SHP2 Inhibition Abrogates MEK inhibitor Resistance in Multiple Cancer Models
Adaptive resistance to MEK inhibitors (MEK-Is) typically occurs via induction of genes for
different receptor tyrosine kinases (RTKs) and/or their ligands, even in tumors of the same …
different receptor tyrosine kinases (RTKs) and/or their ligands, even in tumors of the same …
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Non–small lung cancers (NSCLC) frequently (∼ 30%) harbor KRAS driver mutations, half of
which are KRAS G12C. KRAS-mutant NSCLC with comutated STK11 and/or KEAP1 is …
which are KRAS G12C. KRAS-mutant NSCLC with comutated STK11 and/or KEAP1 is …
CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer
A Prahallad, A Weiss, H Voshol, G Kerr, K Sprouffske… - Cancer Research, 2023 - AACR
Although KRASG12C inhibitors show clinical activity in patients with KRAS G12C mutated
non–small cell lung cancer (NSCLC) and other solid tumor malignancies, response is …
non–small cell lung cancer (NSCLC) and other solid tumor malignancies, response is …
SHP2 Inhibition Abrogates Adaptive Resistance to KRASG12C-Inhibition and Remodels the Tumor Microenvironment of KRAS-Mutant Tumors
ABSTRACT KRAS is the most frequently mutated oncogene in human cancer, and KRAS
inhibition has been a longtime therapeutic goal. Recently, inhibitors (G12C-Is) that bind …
inhibition has been a longtime therapeutic goal. Recently, inhibitors (G12C-Is) that bind …
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers
RJ Nichols, F Haderk, C Stahlhut, CJ Schulze… - Nature cell …, 2018 - nature.com
Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide
spectrum of cancers. While BRAF and MEK inhibitors are efficacious against BRAFV600E …
spectrum of cancers. While BRAF and MEK inhibitors are efficacious against BRAFV600E …
SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models
Adaptive resistance to MEK inhibitors (MEKi) typically occurs via induction of genes for
different receptor tyrosine kinases (RTK) and/or their ligands, even in tumors of the same …
different receptor tyrosine kinases (RTK) and/or their ligands, even in tumors of the same …